Dataset Information

Personalized predictive models for symptomatic COVID-19 patients using basic preconditions: Hospitalizations, mortality, and the need for an ICU or ventilator.

ABSTRACT:

Background

The rapid global spread of the SARS-CoV-2 virus has provoked a spike in demand for hospital care. Hospital systems across the world have been over-extended, including in Northern Italy, Ecuador, and New York City, and many other systems face similar challenges. As a result, decisions on how to best allocate very limited medical resources and design targeted policies for vulnerable subgroups have come to the forefront. Specifically, under consideration are decisions on who to test, who to admit into hospitals, who to treat in an Intensive Care Unit (ICU), and who to support with a ventilator. Given today's ability to gather, share, analyze and process data, personalized predictive models based on demographics and information regarding prior conditions can be used to (1) help decision-makers allocate limited resources, when needed, (2) advise individuals how to better protect themselves given their risk profile, (3) differentiate social distancing guidelines based on risk, and (4) prioritize vaccinations once a vaccine becomes available.

Objective

To develop personalized models that predict the following events: (1) hospitalization, (2) mortality, (3) need for ICU, and (4) need for a ventilator. To predict hospitalization, it is assumed that one has access to a patient's basic preconditions, which can be easily gathered without the need to be at a hospital and hence serve citizens and policy makers to assess individual risk during a pandemic. For the remaining models, different versions developed include different sets of a patient's features, with some including information on how the disease is progressing (e.g., diagnosis of pneumonia).

Materials and methods

National data from a publicly available repository, updated daily, containing information from approximately 91,000 patients in Mexico were used. The data for each patient include demographics, prior medical conditions, SARS-CoV-2 test results, hospitalization, mortality and whether a patient has developed pneumonia or not. Several classification methods were applied and compared, including robust versions of logistic regression, and support vector machines, as well as random forests and gradient boosted decision trees.

Results

Interpretable methods (logistic regression and support vector machines) perform just as well as more complex models in terms of accuracy and detection rates, with the additional benefit of elucidating variables on which the predictions are based. Classification accuracies reached 72 %, 79 %, 89 %, and 90 % for predicting hospitalization, mortality, need for ICU and need for a ventilator, respectively. The analysis reveals the most important preconditions for making the predictions. For the four models derived, these are: (1) for hospitalization:age, pregnancy, diabetes, gender, chronic renal insufficiency, and immunosuppression; (2) for mortality: age, immunosuppression, chronic renal insufficiency, obesity and diabetes; (3) for ICU need: development of pneumonia (if available), age, obesity, diabetes and hypertension; and (4) for ventilator need: ICU and pneumonia (if available), age, obesity, and hypertension.

SUBMITTER: Wollenstein-Betech S

PROVIDER: S-EPMC7442577 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:Neutropenia is a common side effect of myelosuppressive chemotherapy and is associated with adverse outcomes. Early Warning Scores are used to identify at-risk patients and facilitate rapid clinical interventions. Since few Early Warning Scores have been validated in patients with neutropenia, we aimed to create predictive models and nomograms of fever, ICU transfer, and mortality in hospitalized neutropenic patients.DesignDevelopment of statistical prediction models and nomograms using data from a retrospective cohort study of hospitalized patients with neutropenia.SettingUniversity of Virginia Medical Center, a tertiary-care academic medical center in Charlottesville, VA.PatientsThe derivation and validation cohorts included hospitalized adult patients with neutropenia who were admitted to the inpatient wards between October 2010 and January 2015, and April 2017 and April 2020, respectively. We defined neutropenia as an absolute neutrophil count of less than 500 cells/mm3.InterventionsNone.Measurements and main resultsThe derivation cohort included 1,531 hospital admissions in patients with neutropenia. Fever, ICU transfer, and in-hospital mortality occurred in 955 admissions (62%), 297 admissions (19%), and 147 admissions (10%), respectively. In the derivation cohort, the internally validated area under the curves with 95% CI for the fever, ICU transfer, and mortality models were HYPERLINK "callto:0.74%20(0.67-0.84),%200.77"0.74 (0.67-0.84), 0.77 (0.67-0.86), and HYPERLINK "callto:0.95%20(0.0.87-1.0"0.95 (0.0.87-1.0), respectively. The validation cohort included 1,250 admissions in patients with neutropenia. In the validation cohort, the area under the curve (95% CI) for the fever, ICU transfer, and mortality models were HYPERLINK "callto:0.70%20(0.67-0.73),%200.78"0.70 (0.67-0.73), 0.78 (0.72-0.84), and HYPERLINK "callto:0.91%20(0.88-0.94"0.91 (0.88-0.94), respectively. Using these models, we developed clinically applicable nomograms which detected adverse events a median of 4.0-11.4 hours prior to onset.ConclusionsWe created predictive models and nomograms for fever, ICU transfer, and mortality in patients with neutropenia. These models could be prospectively validated to detect high-risk patients and facilitate early clinical intervention to improve patient outcomes.

Project description:OBJECTIVES:To investigate the association between inhaled nitric oxide treatment and ICU mortality and 28-day ventilator-free days in pediatric acute respiratory distress syndrome. DESIGN:Retrospective cohort study. A propensity score for inhaled nitric oxide treatment was developed and used in the analysis. SETTING:Two quaternary care PICUs. PATIENTS:Children with pediatric acute respiratory distress syndrome. INTERVENTIONS:None. MEASUREMENTS AND MAIN RESULTS:There were 499 children enrolled in this study with 143 (28.7%) receiving inhaled nitric oxide treatment. Children treated with inhaled nitric oxide were more likely to have a primary diagnosis of pneumonia (72% vs 54.8%; p < 0.001), had a higher initial oxygenation index (median 16.9 [interquartile range, 10.1-27.3] vs 8.5 [interquartile range, 5.8-12.2]; p < 0.001), and had a higher 72-hour maximal Vasoactive-Inotrope Score (median 15 [interquartile range, 6-25] vs 8 [interquartile range, 0-17.8]; p < 0.001) than those not receiving inhaled nitric oxide. Mortality was higher in the inhaled nitric oxide treatment group (25.2% vs 16.3%; p = 0.02), and children in this group had fewer 28-day ventilator-free days (10 d [interquartile range, 0-18 d] vs 17 d (interquartile range 5.5-22 d]; p < 0.0001). We matched 176 children based on propensity score for inhaled nitric oxide treatment. In the matched cohort, inhaled nitric oxide treatment was not associated with mortality (odds ratio, 1.3 [95% CI, 0.56-3.0]) or 28-day ventilator-free days (incidence rate ratio, 0.91 [95% CI, 0.80-1.04]). These results remained consistent in the entire study cohort when the propensity score for inhaled nitric oxide treatment was used for either inverse probability weighting or stratification in regression modeling with the exception that subjects treated with inhaled nitric oxide were more likely to have 0 ventilator-free days (p ? 0.02). In secondary analysis stratified by oxygenation response, inhaled nitric oxide treatment was not associated with mortality or 28-day ventilator-free days in children with a positive oxygenation response (all p > 0.2) CONCLUSIONS:: Treatment with inhaled nitric oxide in pediatric acute respiratory distress syndrome is not associated with improvement in either mortality or ventilator-free days and may be associated with harm. Further prospective trials are required to define the role of inhaled nitric oxide treatment in pediatric acute respiratory distress syndrome.